Context: How B3 (Brasil, Bolsa, Balcao) works, and what it makes issuers disclose · Brazil on the LatAm Power Map
A doctor opened one hospital in Belo Horizonte in 1980. His grandchildren now run nine across Brazil — and are building a tenth in São Paulo, backed by the country’s biggest insurer.
| Full name | Hospital Mater Dei S.A. |
|---|---|
| Ticker / exchange | MATD3 · B3 (São Paulo), Novo Mercado segment |
| Headquarters | Belo Horizonte, Minas Gerais, Brazil |
| Sector | Healthcare — Medical Care Facilities |
| Employees | Not disclosed in available sources |
| Market value | R$1.59bn (~US$308m) (our calculation) |
| Yearly sales (revenue, TTM) | R$2.25bn (~US$437m) |
| Net profit (FY2025) | R$110.5m (~US$21.5m) (our calculation) |
| Net margin | 5.1% (our calculation) / 5.5% (EODHD TTM) |
| Return on equity | 8.3% |
| Price-to-earnings | 11.1× |
| Dividend yield | 3.2% |
| Website | materdei.com.br · ri.materdei.com.br |
What it is
Rede Mater Dei is an integrated hospital and oncology platform, and one of the largest private hospital networks in Minas Gerais by bed count. It runs about 2,000 beds across nine hospitals in Belo Horizonte, Salvador, Uberlândia, Goiânia, and Feira de Santana.
Services run from hospitalisations and surgeries to oncology, outpatient consultations, and diagnostic exams. Four units carry Joint Commission International accreditation, the global gold standard for hospital quality.
Who owns it
The company is controlled by JSS Empreendimentos e Administração LTDA — the holding vehicle of the founding Salvador family. Insiders hold 82.1% of shares (EODHD); the free float — shares available to outside investors — is roughly 17.5%.
Institutional investors hold about 15.2% of the company (EODHD). The founder, Dr. José Salvador Silva, began formalising succession planning as early as 1998; today ten cousins from the third generation are eligible, but family rules cap the number who may work inside the business at four.
Who runs it
José Henrique Salvador — son of former CEO Henrique Salvador — took the top job in April 2024 as part of a planned handover from the second to the third generation of the family. His father moved to chair the board of directors.
Dr. José Salvador Silva, the founder, holds the honorary title of board president; Henrique Moraes Salvador Silva is board chairman. Rafael Cardoso Cordeiro serves as CFO and investor-relations director.
The money, in plain words
Annual sales are essentially flat — R$2.18bn (US$423 mn) in 2023, R$2.23bn (US$433 mn) in 2024, R$2.18bn (US$423 mn) in 2025 — roughly zero real growth over two years (our calculation). Yet 2024 was a painful outlier: the company booked a net loss of R$338m (US$66 mn), almost certainly driven by large non-cash write-downs, before returning to a R$110.5m (US$21 mn) profit in 2025.
It keeps about 5 cents of profit from every real of sales — a net profit margin of 5.1% (our calculation), modest for a premium hospital chain and a sign that expansion costs are still being absorbed. For every real of owners’ equity the company earns about 8 cents a year — a return on equity of 8.3% — which is below what a private investor might demand, but rising.
The company holds R$599m (~US$116m) in cash on its balance sheet, a meaningful cushion for a network investing in growth. At 11.1 times earnings — a price-to-earnings ratio of 11.1× — the stock trades at a significant discount to Brazilian hospital peers, reflecting the still-thin margins and concentrated ownership.
The dividend yield of 3.2% provides some income while investors wait for margin expansion.
What it is doing now
The single biggest move in play is a joint venture with Bradesco Seguros to build Mater Dei’s first São Paulo hospital — on a former bank branch site in the Santana district — with the new unit expected to open in the second half of 2028. São Paulo is Brazil’s largest private health market; entry there marks a step-change in the network’s ambition.
In June 2026, the board also approved a share buyback programme of up to 9.3 million ordinary shares, equivalent to about 2.8% of total shares issued and 16.1% of the free float. The first quarter of 2026 showed improving momentum: adjusted net profit reached R$36m (US$7 mn), operating profitability rose from 19.3% to 22.6%, and net revenue grew 15% versus the same period a year earlier.
What to watch
- São Paulo build-out cost and timeline. A greenfield hospital in Brazil’s most competitive city is expensive and slow; slippage would pressure cash and margins.
- Margin recovery. With a net margin of 5.1% and ROE of 8.3%, the central question is whether the maturing existing units can drive both numbers meaningfully higher by 2026-27.
- Family governance. Ten cousins, four seats, and a rule requiring each to spend fifteen years rotating through the business before taking a leadership role is admirably disciplined — but any rupture in family consensus would surface quickly in a company with an 82% insider holding and a thin public float.
- Insurer relationships. The Bradesco Seguros joint venture is a strategic bet that deep partnership with a major health insurer can secure patient volume; watch whether similar deals follow.
Sources
- Rede Mater Dei Investor Relations — Overview
- Rede Mater Dei Investor Relations — Historic
- Rede Mater Dei Investor Relations — Administration / Board
- Mater Dei — Diretoria e Conselho
- Dados de Mercado — MATD3 executive profiles
- Seu Dinheiro — Mater Dei São Paulo expansion and succession, January 2025
- Análise de Ações — Share buyback and Q1 2026 results, June 2026
- Oceans14 — MATD3 shareholding and free float data
- Market data: EODHD.
This is news, not investment advice.
Read More from The Rio Times